MEDCAMP S.A.
0.80
PLN
0.00
(0.00%)
MEDCAMP S.A.
NEWCONNECT:MDP
(NewConnect)
Recent
price
0.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- MEDCAMP S.A. is an investment and holding company that operates in commercial real estate redevelopment, property management, and biotechnology research and development, while strategically expanding into advanced emerging technology sectors. Founded in 2007 and headquartered in Poznan, Poland, the company originally operated under the name T2 Investment S.A. before rebranding to MEDCAMP S.A. in 2016. The company is publicly traded on the NewConnect alternative trading system of the Warsaw Stock Exchange under the ticker symbol MDP. The company provides a structured portfolio of products and services across key business segments: commercial real estate operations, comprising the acquisition, revitalization, development, sale, and leasing of commercial real estate, office facilities, and logistics and warehouse spaces; life sciences and biotechnology investment services, including research and experimental development in biotechnology, molecular biology, personalized medicine, genomic sequencing, and bioinformatics; and financial holding services, encompassing corporate restructuring, incubation support, strategic capital allocation, and equity investments in early-stage technology and biotechnology ventures. MEDCAMP S.A. primarily targets commercial tenants, institutional property buyers, biomedical research partners, and technology enterprises across Poland and Central Europe. In its historical biotechnology operations, the company participated in strategic capital and development partnerships, including collaborations involving nanopore sequencing with genXone S.A. as well as oncology diagnostic and therapy tool initiatives with Helix Immuno-Oncology. In recent strategic and corporate developments, MEDCAMP S.A. launched a major strategic transformation to pivot its investment activities toward high-growth technological verticals; the company actively targets opportunities in artificial intelligence and machine learning applications; blockchain and Web3 architectures; biotechnology and life sciences; and deep tech and defense systems. Concurrently, the company executed corporate capital restructuring initiatives, including a reduction of share capital from 26.15 million PLN to 2.615 million PLN, the non-execution of its Series C share issuance, and statutory amendments approved by shareholders. The company also achieved regulatory milestones concerning its NewConnect listing, addressing periodic trading suspensions through the completion of delayed periodic reporting requirements and strengthening corporate governance under its major shareholding group, which includes January Ciszewski and Moonrock Enterprise S.A.